Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Subscribe To Our Newsletter & Stay Updated
